Serum HIF-1α and TGF-β1 levels depending on the clinical and morphological characteristics of breast cancer and sensitivity of tumor to neoadjuvant chemotherapy

Purpose of the study. To assess the serum levels of HIF-1 α and TGF-β1 in patients with invasive breast cancer (BC) depending on the clinical and morphological characteristics, molecular biological subtypes and the degree of pathological response (PR) of the tumor and metastases in the regional lymp...

Full description

Bibliographic Details
Main Authors: E. Yu. Zubareva, M. A. Senchukova, E. V. Virich, M. R. Zubarev, M. A. Goncharova
Format: Article
Language:Russian
Published: QUASAR, LLC 2021-12-01
Series:Исследования и практика в медицине
Subjects:
Online Access:https://www.rpmj.ru/rpmj/article/view/707
_version_ 1826559223566172160
author E. Yu. Zubareva
M. A. Senchukova
E. V. Virich
M. R. Zubarev
M. A. Goncharova
author_facet E. Yu. Zubareva
M. A. Senchukova
E. V. Virich
M. R. Zubarev
M. A. Goncharova
author_sort E. Yu. Zubareva
collection DOAJ
description Purpose of the study. To assess the serum levels of HIF-1 α and TGF-β1 in patients with invasive breast cancer (BC) depending on the clinical and morphological characteristics, molecular biological subtypes and the degree of pathological response (PR) of the tumor and metastases in the regional lymph nodes.Materials and methods. 65 patients with newly diagnosed invasive BC, of whom 32 received from 6 to 8 courses of neoadjuvant chemotherapy (neo-A-CT) were included in this pilot study. The levels of TGF-β1 and HIF-1α were determined by enzyme-linked immunosorbent assay. Statistical analysis was performed using the Statistica 12.0 software.Results. It was found that a high level of TGF-β1 was significantly more often observed in HER2-positive and I-IIa stages of luminal A and triple-negative BC (p = 0.01). HIF-1a levels were significantly higher in the presence of distant metastases (p = 0.04) and slightly higher in the presence of microcalcifications on mammograms (p = 0.07).The analysis showed that patients with grade III-IV of PR in tumor were significantly younger (p = 0.047). Grade III-IV of PR in tumor was significantly more often observed in G3 (p = 0.05), in Her2-positive and triple negative BC (p = 0.01), in the absence of perineural (p = 0.002) and lymphovascular invasion (LVI) (p = 0.045), in the presence of lymphoid infiltration (p = 0.011) and microcalcifications in the tumor (p = 0.043), and slightly higher in ductal BC (p = 0.08). No significant correlations were found between the levels of TGF-β1 and HIF-1a and tumor PR (p = 0.6 and p = 0.9, respectively). However, in patients with grade III-IV of PR in regional metastases, the level of TGF-β1 was significantly lower than in patients with grade I-II (p = 0.03).Conclusions. Thus, these data indicate the presence of correlations between the levels of HIF-1 α and TGF-β1 in the blood serum and a number of clinical characteristics of BC. The highest levels of HIF-1α are observed in the presence of distant metastases, and the highest levels of TGF-β1 are noted in HER2-positive and I-IIa stages of luminal A and triple-negative breast cancer. Given the presence of significant correlations between the level of TGF-β1 and the degree of PR in regional lymph nodes, its determination may be useful for assessing the sensitivity of metastases to regional lymph nodes to the neo-A-CT.
first_indexed 2024-04-10T01:25:12Z
format Article
id doaj.art-9b33de62c41d48f1862b099f2fd3b532
institution Directory Open Access Journal
issn 2410-1893
language Russian
last_indexed 2025-03-14T08:56:58Z
publishDate 2021-12-01
publisher QUASAR, LLC
record_format Article
series Исследования и практика в медицине
spelling doaj.art-9b33de62c41d48f1862b099f2fd3b5322025-03-02T12:44:11ZrusQUASAR, LLCИсследования и практика в медицине2410-18932021-12-0184536410.17709/2410-1893-2021-8-4-5420Serum HIF-1α and TGF-β1 levels depending on the clinical and morphological characteristics of breast cancer and sensitivity of tumor to neoadjuvant chemotherapyE. Yu. Zubareva0M. A. Senchukova1E. V. Virich2M. R. Zubarev3M. A. Goncharova4Orenburg Regional Clinical Oncological Dispensary; Orenburg State Medical UniversityOrenburg Regional Clinical Oncological Dispensary; Orenburg State Medical UniversityOrenburg Regional Clinical Oncological DispensaryOrenburg Regional Clinical Oncological DispensaryOrenburg Regional Clinical Oncological DispensaryPurpose of the study. To assess the serum levels of HIF-1 α and TGF-β1 in patients with invasive breast cancer (BC) depending on the clinical and morphological characteristics, molecular biological subtypes and the degree of pathological response (PR) of the tumor and metastases in the regional lymph nodes.Materials and methods. 65 patients with newly diagnosed invasive BC, of whom 32 received from 6 to 8 courses of neoadjuvant chemotherapy (neo-A-CT) were included in this pilot study. The levels of TGF-β1 and HIF-1α were determined by enzyme-linked immunosorbent assay. Statistical analysis was performed using the Statistica 12.0 software.Results. It was found that a high level of TGF-β1 was significantly more often observed in HER2-positive and I-IIa stages of luminal A and triple-negative BC (p = 0.01). HIF-1a levels were significantly higher in the presence of distant metastases (p = 0.04) and slightly higher in the presence of microcalcifications on mammograms (p = 0.07).The analysis showed that patients with grade III-IV of PR in tumor were significantly younger (p = 0.047). Grade III-IV of PR in tumor was significantly more often observed in G3 (p = 0.05), in Her2-positive and triple negative BC (p = 0.01), in the absence of perineural (p = 0.002) and lymphovascular invasion (LVI) (p = 0.045), in the presence of lymphoid infiltration (p = 0.011) and microcalcifications in the tumor (p = 0.043), and slightly higher in ductal BC (p = 0.08). No significant correlations were found between the levels of TGF-β1 and HIF-1a and tumor PR (p = 0.6 and p = 0.9, respectively). However, in patients with grade III-IV of PR in regional metastases, the level of TGF-β1 was significantly lower than in patients with grade I-II (p = 0.03).Conclusions. Thus, these data indicate the presence of correlations between the levels of HIF-1 α and TGF-β1 in the blood serum and a number of clinical characteristics of BC. The highest levels of HIF-1α are observed in the presence of distant metastases, and the highest levels of TGF-β1 are noted in HER2-positive and I-IIa stages of luminal A and triple-negative breast cancer. Given the presence of significant correlations between the level of TGF-β1 and the degree of PR in regional lymph nodes, its determination may be useful for assessing the sensitivity of metastases to regional lymph nodes to the neo-A-CT.https://www.rpmj.ru/rpmj/article/view/707breast cancerneoadjuvant chemotherapypathological response of the tumor and metastasesserum tgf-p1 and hif-1α levelsenzyme immunoassay
spellingShingle E. Yu. Zubareva
M. A. Senchukova
E. V. Virich
M. R. Zubarev
M. A. Goncharova
Serum HIF-1α and TGF-β1 levels depending on the clinical and morphological characteristics of breast cancer and sensitivity of tumor to neoadjuvant chemotherapy
Исследования и практика в медицине
breast cancer
neoadjuvant chemotherapy
pathological response of the tumor and metastases
serum tgf-p1 and hif-1α levels
enzyme immunoassay
title Serum HIF-1α and TGF-β1 levels depending on the clinical and morphological characteristics of breast cancer and sensitivity of tumor to neoadjuvant chemotherapy
title_full Serum HIF-1α and TGF-β1 levels depending on the clinical and morphological characteristics of breast cancer and sensitivity of tumor to neoadjuvant chemotherapy
title_fullStr Serum HIF-1α and TGF-β1 levels depending on the clinical and morphological characteristics of breast cancer and sensitivity of tumor to neoadjuvant chemotherapy
title_full_unstemmed Serum HIF-1α and TGF-β1 levels depending on the clinical and morphological characteristics of breast cancer and sensitivity of tumor to neoadjuvant chemotherapy
title_short Serum HIF-1α and TGF-β1 levels depending on the clinical and morphological characteristics of breast cancer and sensitivity of tumor to neoadjuvant chemotherapy
title_sort serum hif 1α and tgf β1 levels depending on the clinical and morphological characteristics of breast cancer and sensitivity of tumor to neoadjuvant chemotherapy
topic breast cancer
neoadjuvant chemotherapy
pathological response of the tumor and metastases
serum tgf-p1 and hif-1α levels
enzyme immunoassay
url https://www.rpmj.ru/rpmj/article/view/707
work_keys_str_mv AT eyuzubareva serumhif1aandtgfb1levelsdependingontheclinicalandmorphologicalcharacteristicsofbreastcancerandsensitivityoftumortoneoadjuvantchemotherapy
AT masenchukova serumhif1aandtgfb1levelsdependingontheclinicalandmorphologicalcharacteristicsofbreastcancerandsensitivityoftumortoneoadjuvantchemotherapy
AT evvirich serumhif1aandtgfb1levelsdependingontheclinicalandmorphologicalcharacteristicsofbreastcancerandsensitivityoftumortoneoadjuvantchemotherapy
AT mrzubarev serumhif1aandtgfb1levelsdependingontheclinicalandmorphologicalcharacteristicsofbreastcancerandsensitivityoftumortoneoadjuvantchemotherapy
AT magoncharova serumhif1aandtgfb1levelsdependingontheclinicalandmorphologicalcharacteristicsofbreastcancerandsensitivityoftumortoneoadjuvantchemotherapy